



Alchemedicine Executes License Agreement with Eisai and Closes 2.3M USD Seed Financing

Tsukuba City, Japan – October 28, 2019 –

Alchemedicine, Inc. (Tsukuba City, Ibaraki; CEO, Keigo Tanaka; "Alchemedicine") has entered into a license agreement with Eisai Co. Ltd. about the patents of synthetic reagents and lead compounds for a wide range of diseases. In addition, Alchemedicine has raised financing through a third-party allotment to Beyond Next Ventures Inc. and Mitsubishi UFJ Capital Co., Ltd. in a seed round, a total of approximately 2.3 million USD.

Alchemedicine, carve-out biotech from Eisai Co. Ltd., is a drug discovery biotech dedicated to discovering novel small molecule drugs having better profiling compared to existing drugs with compound design in unique chemical space. Alchemedicine was selected for Blockbuster TOKYO 2018, an acceleration program for supporting the foundation of medical biotechs sponsored by the Tokyo Metropolitan Government and operated by Beyond Next Ventures, and taking that opportunity, Alchemedicine was founded in April 2019.

Alchemedicine will accelerate the discovery of innovative drugs through collaborative work with external business partners and research institute to address unmet medical needs in the clinic.

For more information, please contact info@alchemedicine.com